Products from BPS Bioscience require a minimum order value above 400€
Application: Use as a control in CAR-T or NK co-culture killing assays.
Background: The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells.CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for several B-cell malignancies, including B-cell lymphomas, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B-cell populations and manage B-cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.
Description: CD20 Knockout Raji Cell Line is a Raji cell line where CD20 (B-lymphocyte antigen CD20, or MS4A1) has been genetically removed from Raji cells using CRISPR/Cas9 genome editing. This cell line has been validated by genome sequencing and flow cytometry.
Host Cell Line: Raji
Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Uniprot: P11836
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
English
Deutsch
